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The fine particle dose delivered via dry powder inhalers (DPIs) is often affected by the inspiratory flow rate
generated during inhalation. This has clinical implications, since the fine particle dose determines the amount of
drug reaching the lungs. With Easyhaler1 DPI the fine particle dose remains relatively constant over the range of
inspiratory flow rates from 30–60 lmin71. The aim of this study was to confirm that clinical ecacy is maintained
even at low flow rates by comparing the bronchodilating effect of salbutamol (100 mg) delivered via Easyhaler1 at a
target inspiratory flow of 30 lmin71 with the same dose of salbutamol via pressurised metered-dose inhaler (pMDI)
plus spacer.
This was a double-blind, randomized, cross-over study with double-dummy technique. Twenty-one paediatric
and adult asthmatic patients completed the study, which was conducted over 2 study days. The main outcome
parameter was forced expiratory volume in 1 sec (FEV1). The patients were trained to generate a low peak
inspiratory flow rate (PIFR) of 30 lmin71, and the actual PIFR through Easyhaler1 was recorded.
The average PIFR through Easyhaler1 was 28?7 lmin71. The difference in the maximum value of FEV1
(FEV1max) between the treatments after drug inhalation was 0?01 l. The mean of FEV1max was 2?67 l after pMDI
plus spacer compared to 2?69 l after Easyhaler1. Improvements in FEV1 were clinically significant. No significant
differences between treatments were found.
A reasonably low inspiratory flow rate through Easyhaler1 produces an equivalent improvement in lung
function to a correctly used pMDI plus spacer. Hence, Easyhaler1 can be used with confidence in patients who may
have diculty in generating a high inspiratory flow rate, such as children and the elderly.
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Increasingly, dry powder inhalers (DPIs) are prescribed in
preference to traditional aerosols — pressurized metered-
dose inhalers (pMDIs) — which are associated with a
number of problems. These include sub-optimal use
resulting from the failure of patients to properly co-
ordinate inhaler actuation with inspiration (1–3), and the
unacceptable environmental effects of chlorofluorocarbons
(4). In addition, the propellants and lubricants in pMDIs
can result in paradoxical, acute bronchoconstriction in
some patients (5–9).
While DPIs can overcome the drawbacks of pMDIs, it is
essential that the potential therapeutic benefit of the deviceReceived 29 June 2000 and accepted in revised form 24 August
2000.
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0954-6111/00/121229+05 $35?00/0can be obtained at an achievable inspiratory flow rate, since
inspiratory flow rate is known to affect the amount of drug
deposited in the lungs (10–14). As target inspiratory flow
rate varies between different inhalers as a function of the
resistance of the device, the objective of this study was to
investigate the relationship between inspiratory flow rate
and clinical ecacy for the new-generation DPI, Easy-
haler1.
Easyhaler1 is a multidose DPI with 200 preloaded doses.
The device has been designed to resemble a pMDI (Fig. 1).
However, Easyhaler1 does not require the patient to co-
ordinate drug release and inhalation. Easyhaler1 has a dose
counter showing the remaining doses in the inhaler, and
uses lactose as an excipient to enable consistent drug
delivery.
In an open study among asthmatic children with very low
inspiratory flow rate, salbutamol inhaled via Easyhaler1
was shown to produce equivalent bronchodilatation to
salbutamol via pMDI (15). Hence, the aim of this study was
to confirm that the clinical ecacy of salbutamol is
maintained at low flow rates through Easyhaler1.
The bronchodilating effect of salbutamol (100 mg) via# 2000 HARCOURT PUBLISHERS LTD
FIG. 1. Easyhaler1 multidose powder inhaler.
TABLE 1. Demographics and baseline features at the
beginning of the study (n=22)
Gender (male/female) 10/12
Age (years) 19 (7–65)*
— number of patients under 16 years 12
Height (cm) 155 (120–183)*
Weight (kg) 51 (20–96)*
Number of atopic subjects 17
Severity of asthma (mild/ moderate) 7/15
Duration of asthma symptoms (years) 5.6 (6.8){
Duration of asthma (years since
diagnosis)
5.1 (7.2){
Values are means+range* or SD{ (range or SD shown in
parentheses), except in relation to sex, number of atopic
subjects or severity of asthma.
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with the same dose of salbutamol via pMDI plus spacer.
Methods
SUBJECTS
Twenty-two paediatric and adult outpatients with diag-
nosed bronchial mild or moderate asthma were enrolled
into the study (Table 1). The severity of asthma was graded
according to the International Consensus Report on
Diagnosis and Treatment of Asthma (16). Twenty-one
patients completed the study and one was excluded due to a
protocol violation. The study included both male and
female patients aged from seven to 65 years. None had
smoked during the 6 months prior to the study. In the 4
weeks prior to the study, all patients had shown an
improvement of at least 15% in forced expiratory volume
in 1 sec (FEV1) or peak expiratory flow (PEF) following
inhalation of a sympathomimetic.
The study was conducted according to the principles of
the current revision of the Declaration of Helsinki of the
World Medical Assembly. The independent local Ethical
Committee approved the study protocol. All patients
received oral and written information about the study and
gave their written informed consent to participation before
entering into the study.
STUDY DESIGN
The study was conducted according to a randomized,
double-blind with double-dummy technique, cross-over
design with a single dose regimen and two treatment
periods. The study was carried out at The Skin and Allergy
Hospital, HUCH, Finland. The investigational drug was
100 mg salbutamol via Easyhaler1 (Buventol Easyhaler1
100 mg/dose, Orion Pharma, Finland). The comparativedrug was 100 mg salbutamol via pMDI with a holding
chamber (Ventolin1 100 mg/dose with Volumatic1, Glaxo
Wellcome, U.K.). Placebos of both devices were also used.
The study was carried out on two study days separated
by an interval of at least 24 h. The study began at the same
time on both study days. The patients were randomly
divided into two groups to receive salbutamol via Easy-
haler1 and via pMDI plus spacer. On each study day, the
patients inhaled first one dose from Easyhaler1 and then a
dose from the pMDI plus spacer, with either of the devices
being placebo. The lung function tests were measured
before inhalation and three times during a 1-h period
thereafter.
The investigational drug was inhaled with a low peak
inspiratory flow rate (PIFR) targeted at 30 lmin71. Patients
were taught the correct inhalation technique to achieve the
target flow rate using an empty Easyhaler1 in an air-tight
chamber connected in series with a pneumotachograph
(Spirotrack III, Vitalograph Ltd, U.K.). The drug dose
from the pMDI plus spacer was inhaled within 1 sec
following actuation with a low and deep inspiration
according to the manufacturer’s instructions.
Before the study measurements, patients abstained from
controlled-release theophylline preparations for at least
48 h, from oral and inhaled long-acting sympathomimetics,
sodium cromoglycate and nedocromil sodium for at least
12 h, and from inhaled short-acting sympathomimetics for
at least 6 h. The use of oral, inhaled and topical
corticosteroids, and the treatment of concomitant diseases,
were unchanged during the study. The patients were not
allowed to drink caffeine-containing drinks for 4 h before
the lung function tests.
METHODS
FEV1, PEF and forced vital capacity (FVC) were measured
with a flow volume spirometer immediately before, and 15,
30 and 60min after inhalation of the study drug. Two
exhalations with a variation in FEV1 of less than 5% were
performed and the best values were used for analysis. The
difference in baseline FEV1 values between the study days
FIG. 2. Change in FEV1 during the follow-up period of
60min following inhalation of a 100 mg dose of
salbutamol via Easyhaler1 at low peak inspiratory flow
(target 30 lmin71), or from pMDI plus spacer
(mean+SEM; n = 21). -~- : Easyhaler1; -*- : MDI plus
spacer.
EASYHALER UNAFFECTED BY LOW INSPIRATORY FLOW 1231had to be less than 15%. PIFR through Easyhaler1 was
measured on both study days. Adverse events (AEs) were
recorded at the end of each study day as safety parameters.
ANALYSIS
The null hypothesis in this study was that the two study
drug-delivery device combinations had different broncho-
dilating effects. The alternative hypothesis assumed equiva-
lence of the drug-device combinations. Both primary and
secondary ecacy variables were used to collect evidence
against the null hypothesis. The primary determinant of
therapeutic ecacy was the maximum value of FEV1
(FEV1max). Secondary variables included the area under the
FEV1 curve for the follow-up time, and FEV1max as a
percentage of the predicted value at baseline (during the
first study day). FVCmax and PEFmax were treated as
secondary variables.
A sample size of at least 17 patients was required to
generate the statistical power necessary to detect a
difference of 0?125 l in FEV1 at the 5% significance level
with 90% power. Analysis of the primary ecacy variable
was performed using both Intention-To-Treat (ITT) and
Per Protocol (PP) data sets. Other analyses were performed
only for the ITT population. There were 17 patients in the
PP data set and 21 in the ITT data set. An analysis of
variance (ANOVA) model adapted for cross-over design
was used for the statistical analysis of variables.
Results
PEAK INSPIRATORY FLOW RATE AND
LUNG FUNCTION PARAMETERS
There was no significant difference in the primary ecacy
variable between the PP and ITT data sets and, therefore,
only results from ITT data set are presented. The mean
(+SD) PIFR through Easyhaler1 measured during the
administration of active study treatment was 28?7
(+5?1) lmin71. The mean (+SD) of FEV1max after the
inhalation of salbutamol from Easyhaler1 was increased
from 2?44 to 2?69 (+0?93) l, and after inhalation from
pMDI plus spacer from 2?43 to 2?67 (+0?97) l (Table 2).
The estimated difference in FEV1max between Easyhaler
1TABLE 2. Analyses of FEV1 [with the exception of the AUC dat
follow-up period. Values are means (SD)]
Easyhaler (n=21–22
At baseline After
FEV1 (l) 2?44 (0?90) 2?69
FEV1 of predicted (%) 80?9 (10?9) 89?5
AUC of FEV1 (l min) — 10?2and pMDI plus spacer was 0?01 l (90% confidence interval
from 70?07 to 0?06 l). Both treatment groups showed a
clinically significant (40?230 l) (17) improvement in FEV1
within the first 15min following inhalation of salbutamol.
During the next 45min there were no further significant
changes (Fig. 2). The mean AUC of FEV1 during the
follow-up time was almost equal after Easyhaler1 and
pMDI plus spacer, 10?2 and 10?1, respectively (Table 2).
The estimated difference in AUC of FEV1 between Easy-
haler1 and pMDI plus spacer was 0?9 (90% confidence
interval from 0?6 to 0?12).
FVC did not change significantly during the study (Table
3). In both groups, the mean of the FVCmax was close to the
predicted and baseline values of FVC. The PEF results
paralleled the FEV1 data (Table 3). No significant
differences in primary or secondary ecacy variables were
found between the treatments.
TOLERABILITY
All patients, including the one patient withdrawn after the
first study day for protocol violation, were included in the
safety analysis. No adverse events were reported duringa, the after treatment value is the maximum value during the
) MDI with spacer (n=21–22)
treatment At baseline After treatment
(0?93) 2?43 (0?90) 2?67 (0?97)
(10?7) 80?0 (12?3) 88?0 (11?7)
(9?1) — 10?1 (9?0)
TABLE 3. Analyses of PEF and FVC [with the exception of the AUC data the after treatment value is the maximum value
during the follow-up period. Values are means (SD)]
Easyhaler (n=21–22) MDI with spacer (n=21–22)
At baseline After treatment At baseline After treatment
FVC (l) 3?26 (1?17) 3?35 (1?19) 3?25 (1?17) 3?31 (1?18)
FVC of predicted (%) 97?0 (10?3) 99?9 (10?1) 96?7 (10?4) 98?5 (10?8)
AUC of FVC (l min) — 0?9 (7?0) — 70?8 (6?6)
PEF (l min71) 300 (123) 337 (142) 295 (124) 338 (142)
PEF of predicted (%) 71?4 (12?5) 79?7 (14?6) 69?9 (14?9) 79?8 (14?9)
AUC of PEF (l min) — 1462 (1523) — 1591 (1510)
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safe and without any significant adverse drug reactions
following a single 100 mg dose.
DISCUSSION
In this study, the bronchodilating effect of two different
types of salbutamol inhaler was compared in paediatric and
adult asthmatic patients. The pMDI plus large volume
spacer was used optimally according to the manufacturer’s
instructions. However, for this study Easyhaler1 DPI was
used at a lower inspiratory flow rate (targeted 30 lmin71)
than is normally recommended. Hence, the study is likely to
reflect the real situation where a patient’s ability to inhale is
diminished, such as with a small child, or a person having
an acute asthma attack. The lowest available dose of
salbutamol via MDI and Easyhaler1, 100 mg, was used in
the study trying to ensure that subjects are on a steep part
of the dose–response curve instead of the plateau. However,
there is a possibility that subjects would have achieved a
maximal response.
There is considerable variability between DPIs in the
effect of inspiratory flow rate on drug deposition and
clinical ecacy. For example, with Turbuhaler1 (Astra
Draco, Sweden), which is one of the most widely used DPIs,
the lung deposition of budesonide and terbutaline has been
shown to decrease by half at low (28–36 lmin71) inspira-
tory flow compared to the optimal inspiratory flow rate of
60 lmin71 (10,11). Similarly, the clinical ecacy of
formoterol dry powder inhaled from Aerolizer1 DPI
(ITALSEBER Farmaceutici Italy) is flow-dependent (12).
In contrast, the clinical ecacy of another widely used DPI,
DiskusTM (AccuhalerTM; Glaxo Wellcome, U.K.) has been
reported to be almost flow-independent (18). Clickhaler1
DPI (ML Laboratories PLC, U.K.) which is based on
similar operating principles to Easyhaler1, has also been
shown to be flow-independent in a study comparing the
bronchodilating effect of 200 mg of salbutamol inhaled from
Clickhaler1, and pMDI (19). However, the high dose used
(200mg) diminishes the power of the result.
The fine particle dose from the Easyhaler1 is only
slightly influenced by the inspiratory flow rate in vitro (20).The respirable fraction at a flow rate of 28 lmin71 was
found to be approximately 70% of the respirable fraction
created at the maximum PIFR (60 lmin71) through Easy-
haler1 (21). In a previous clinical study, Buventol Easy-
haler1 200 mg dose71 produced a clear bronchodilating
effect with a PIFR value as low as 16 lmin71 (15). It should
be noted that due to high internal resistance of the
Easyhaler1 greater inspiratory effort is required to achieve
the same inspiratory flow rate through the Easyhaler1 than
needed for a gentle inhalation using a MDI and a spacer.
However, a sub-optimal inspiratory flow rate of about
30 l min71 through the Easyhaler1 is achieved very easily
(15). The results of the present study with Easyhaler1 are
consistent with previous results showing equivalent clinical
effect to a pMDI plus spacer (20,22,23). The primary
equivalence criterion, FEV1max was clearly within prede-
fined limits.
There was no correlation between age, or PIFR and the
relative treatment effect of the two devices. In the present
study, even a PIFR as low as 23 lmin71 through Easy-
haler1 is sucient to obtain a similar treatment effect to
normal inhalation from a pMDI plus spacer.
Conclusions
Even a reasonably low peak inspiratory flow rate
(29 lmin71) through Easyhaler1 produces an equivalent
improvement in lung function to a correctly used pMDI
plus spacer. Hence, Easyhaler1 can be used with confidence
in patients who may have diculties in generating high
levels of inspiratory flow rate, such as children and the
elderly.
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